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ABSTRACT
Background
Mild cognitive impairment (MCI) refers to a transitional zone between normal ageing and
dementia. Despite the uncertainty regarding the definition of MCI as a clinical entity, clinical
trials have been conducted in the attempt to study the role of cholinesterase inhibitors (ChEIs)
currently approved for symptomatic treatment of mild to moderate Alzheimer disease (AD), in
preventing progression from MCI to AD. The objective of this review is to assess the effects of
ChEIs (donepezil, rivastigmine, and galantamine) in delaying the conversion from MCI to
Alzheimer disease or dementia.
Methods and Findings
The terms ‘‘donepezil’’, ‘‘rivastigmine’’, ‘‘galantamine’’, and ‘‘mild cognitive impairment’’
and their variants, synonyms, and acronyms were used as search terms in four electronic
databases (MEDLINE, EMBASE, Cochrane, PsycINFO) and three registers: the Cochrane
Collaboration Trial Register, Current Controlled Trials, and ClinicalTrials.gov. Published and
unpublished studies were included if they were randomized clinical trials published (or
described) in English and conducted among persons who had received a diagnosis of MCI and/
or abnormal memory function documented by a neuropsychological assessment. A stand-
ardized data extraction form was used. The reporting quality was assessed using the Jadad
scale. Three published and five unpublished trials met the inclusion criteria (three on donepezil,
two on rivastigmine, and three on galantamine). Enrolment criteria differed among the trials, so
the study populations were not homogeneous. The duration of the trials ranged from 24 wk to
3 y. No significant differences emerged in the probability of conversion from MCI to AD or
dementia between the treated groups and the placebo groups. The rate of conversion ranged
from 13% (over 2 y) to 25% (over 3 y) among treated patients, and from 18% (over 2 y) to 28%
(over 3 y) among those in the placebo groups. Only for two studies was it possible to derive
point estimates of the relative risk of conversion: 0.85 (95% confidence interval 0.64–1.12), and
0.84 (0.57–1.25). Statistically significant differences emerged for three secondary end points.
However, when adjusting for multiple comparisons, only one difference remained significant
(i.e., the rate of atrophy in the whole brain).
Conclusions
The use of ChEIs in MCI was not associated with any delay in the onset of AD or dementia.
Moreover, the safety profile showed that the risks associated with ChEIs are not negligible. The
uncertainty regarding MCI as a clinical entity raises the question as to the scientific validity of
these trials.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org November 2007 | Volume 4 | Issue 11 | e338 1818
PLoS MEDICINEIntroduction
Alzheimer disease (AD) is a neurodegenerative disorder
characterized by cognitive and memory deterioration, pro-
gressive impairment of activities of daily living, and a
multiplicity of behavioural and psychological disturbances.
AD is the main cause of dementia syndrome and one of the
most burdensome conditions of later life. In a recent Delphi
consensus study, based on a systematic review of the
literature on the prevalence of dementia, the authors
estimated that more than 24 million people worldwide
currently have dementia [1]. Dementia is also the leading
cause of disability in persons aged 60 y and older, and its
direct and indirect costs are very high [2,3].
There exists little evidence of modiﬁable risk factors for
AD [1]; disease-modifying therapies are not available [4], and
of the symptomatic therapies the efﬁcacy of cholinesterase
inhibitors (ChEIs—donepezil, rivastigmine, and galantamine)
in mild-to-moderate AD patients is questionable and has
been widely debated [5,6].
In recent years, efforts have been made to study individuals
believed to be at greater risk of developing dementia and who
were considered as having mild cognitive impairment (MCI),
which refers to a transitional zone between normal ageing
and dementia [7–9]. However, widely accepted and validated
criteria for diagnosing MCI do not exist, and the differences
between this term and the other clinical labels given to the
cognitive dysfunctions associated with aging are not clear
(e.g., benign senescent forgetfulness, age-associated memory
impairment, age-associated cognitive decline, mild cognitive
decline, mild neurocognitive decline, and cognitive impair-
ment no dementia) [10–14].
A number of longitudinal studies have attempted to
estimate the rate of conversion from MCI to dementia. When
comparing the different studies, the conversion rates vary
greatly (from 9% to 40%) because of differences in sampling
criteria, the case deﬁnition, the length of follow-up, assess-
ment procedures, and the number of persons lost to follow-
up. Moreover, up to 40% of MCI cases reverted to a normal
cognitive condition within 2–3 y [15–18].
Despite the uncertainty regarding the deﬁnition of MCI as
a clinical entity, clinical trials on ChEIs as a preventive
treatment have been conducted in the attempt to study the
possible role of these agents in slowing the onset of AD,
because of the purported pathophysiological relationship
between MCI and AD. The ﬁrst published trials showed that
these agents were not efﬁcacious, yet the authors attributed
these ﬁndings mainly to methodological issues, such as the
selection of homogeneous samples, the deﬁnition of reliable
outcomes, and the duration of treatment [19]. The substantial
failure of these attempts was recently conﬁrmed by two
Cochrane systematic reviews, one on galantamine and the
other on donepezil [20,21].
On the basis of the results obtained in the clinical trials on
galantamine, in 2005 the US Food and Drug Administration
[22] and health authorities all over the world issued a safety
warning advising that galantamine should be used only for
the approved indications of mild to moderate AD, and that
for other possible indications (e.g., MCI) the risks may
outweigh the beneﬁt. Nevertheless, the suitability of using
ChEIs to treat persons labelled with MCI continues to be
widely debated [23–26].
Most of the trials conducted on the efﬁcacy of donepezil,
galantamine, and rivastigmine on MCI remain unpublished
even after years from their conclusion. As a consequence, the
original data are not available for researchers or physicians
who could use these drugs in their clinical practice. In this
context, we conducted a systematic review of published and
unpublished trials on ChEIs, so as to provide an update on
the risk–beneﬁt proﬁle for this drug class (donepezil, galant-
amine, and rivastigmine) in treating MCI.
Methods
Search Strategy
In February of 2006, we searched for the terms ‘‘donepe-
zil’’, ‘‘rivastigmine’’, ‘‘galantamine’’ and ‘‘mild cognitive
impairment’’, and their variants, synonyms, and acronyms
in the following sources: (1) four electronic databases—
MEDLINE (http://www.pubmed.gov/; 1990 to February 2006),
EMBASE (http://www.embase.com/; 1990 to February 2006),
The Cochrane Collaboration (http://www.cochrane.org/index.
htm), and PsycINFO (http://www.apa.org/psycinfo/); and (2)
three registers—in particular, the Cochrane Collaboration
Trial Register (http://www.thecochranelibrary.com/), Current
Controlled Trials (http://www.controlled-trials.com/), and
Clinicaltrials.gov (http://www.clinicaltrials.gov/). We also ex-
amined the bibliographies of all of the considered publica-
tions so as to identify other studies. We did not consider
tacrine in our search, because it is no longer used in clinical
practice, because of its high toxicity [27,28].
Inclusion Criteria
Published and unpublished studies were included if they
were: randomised controlled trials (RCTs) of cholinesterase
inhibitors (donepezil, rivastigmine, galantamine); written in
English; and conducted among persons with abnormal
memory function documented by a neuropsychological
assessment and/or who met diagnostic criteria for MCI.
All studies were required to have as an outcome measure
the time to development of dementia or of possible or
probable AD, or the improvement of measurement concern-
ing cognitive/clinical/neuropsychiatric domains, and/or im-
provements based on neuroimaging examinations.
Exclusion Criteria
Studies were excluded if the design was not an RCT; the
study did not present original data; the study drug was not a
ChEI; and participants were cognitively normal for age or had
already been classiﬁed as having dementia of any type.
Ongoing studies were not included in the review.
Data Extraction
We screened the obtained titles, abstracts, and protocols.
Data were extracted using a standardized data extraction
form that was developed by all authors. The extracted
information included doses of medication; duration of the
trial; the number, age, and gender of participants; enrolment
criteria; funding sources; primary and secondary outcomes;
all-cause dropouts; adverse events; and deaths occurring
during the study period. The data were extracted and
summarized by two investigators (EA and NV) not blinded
to the study’s authors or to the publication status. To ensure
that accurate data were obtained, a third investigator (RR)
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through discussions among all investigators.
Data Analysis
When available, we recorded for each outcome the mean
difference between baseline and follow-up measures for the
individual study arms, and the standard deviation of each
difference. When the standard deviation was not given it was
estimated from the standard error. For each outcome the
effect measure was estimated as the mean difference between
treated and placebo groups. A Bonferroni correction for
multiple comparisons was done for the individual tests within
the same study.
We have not included any estimate of pooled effect because
of clinical heterogeneity among the populations enrolled in
the trials included in the review.
Statistical analyses were conducted by using Stata software
8.0 (Stata, College Station, Texas, United States).
Assessment of Methodological Quality
To roughly measure the quality of the study design/
reporting of each trial, we used the validated scale developed
by Jadad and colleagues, which assigns a numerical score of 0–
5 (5 being the best score) [29].
Results
Search Flow
The literature search yielded 157 potentially relevant
citations: 109 studies from electronic databases and 48 from
clinical trial registers. The selection process is illustrated in
Figure 1. Of the 157 citations, 124 were excluded either
because they were not RCTs (n¼119) or participants did not
have MCI (ﬁve studies). After having evaluated the full text of
the 33 remaining studies, we excluded 25 studies for the
following reasons. Four were duplicates of other studies; nine
had not been conducted among MCI patients (in most cases
participants had already received a diagnosis of AD); six were
not RCTs (three were comments or editorials on existing
studies, and three were observational studies); one was
conducted among persons not treated with ChEIs; and ﬁve
trials were still ongoing.
Characteristics of the Trials and Participants
The eight trials that investigated the efﬁcacy and safety of
ChEIs (three on donepezil, two on rivastigmine, and three on
galantamine) in persons with MCI were included in the review
(Table 1) [30–37]. Of these, three were published in peer-
reviewed journals [34,36,37], and ﬁve were retrieved from
clinical trial registers [30–33,35]. Regrettably, extensive
synopses were available for only three of these ﬁve trials
[31–33], whereas for the other two we were able to retrieve
only a brief description of the principal characteristics
[30,35]. Additional information were sought unsuccesfully
from the original investigators and from the investigators’
institutions. For this reason, these two trials are not always
included when discussing the results. Notably, one of them
was suspended, yet we were not able to obtain information
from the manufacturers on the reasons for suspension [35].
The main characteristics of the eight trials are presented in
Table 1. All trials but one were totally or partially sponsored
by pharmaceutical companies [30]. The duration of the trials
on donepezil was 24 wk, 1 y, and 3 y. Dosage was reported in
two of these trials (10 mg/d after a starting dose of 5 mg/d)
Figure 1. Trials Identification and Selection Process
doi:10.1371/journal.pmed.0040338.g001
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Mild Cognitive Impairment: A Review[36,37]. One of the three trials [34] on galantamine differed
from the other two [32,33] in duration (16 wk versus 2 y),
whereas dosages were identical in all three (16–24 mg/day).
One of the two trials on rivastigmine lasted 3–4 y and applied
dosages between 3 and 12 mg/d [31]; for the other trial, we
were not able to retrieve information on either duration or
dosage [35]. Of the six trials for which dosage was reported, in
three, once the maximum dosage was reached, treatment
continued with that dosage [34,36,37], whereas in the other
three trials, the dosage remained ﬂexible (16 or 24 mg for
galantamine and 3–12 mg for rivastigmine) [31–33].
One trial was carried out in only one site [34]; the two
published studies on donepezil were conducted in 22 and 69
centres, respectively [36,37]. One of the unpublished studies
on rivastigmine was conducted in 69 centres. For the
remaining four trials, this information was not available.
The number of participants ranged from 19 to 1,062 and
varied greatly among the trials. In all trials, all participants
were greater than 50 y of age. When reported, the percentage
of females ranged from 42% to 52%; in one trial, all 19
participants were males [34].
All studies enrolled patients accordingly to the Petersen’s
criteria: not demented, memory complaint, preserved general
cognitive function, intact activities of daily living, impaired
memory for age and education [9]. However, the operation-
alisation of the MCI diagnostic criteria differed widely among
the trials (Table 1). Cognitive functions were assessed using
the mini mental state examination (MMSE) with different cut-
offs [34–35], or the clinical dementia rating (CDR) scale [31–
33], or both [36,37]. Activities of daily living were assessed in
two studies using two different scales (ADCL-ADL-MCI and
ADL) [36,37]. The assessment of memory was based on the
New York University paragraph recall test (immediate and
delayed) in three studies [31–33], with two different cut-off
scores, or on the Wechsler Memory Scale (Revised) Logical
Memory delayed recall test [37]; three trials used two
unspeciﬁed memory tests [32,33,35].
Only three of the trials [31,36,37] ascertained the psychi-
atric proﬁle of participants, yet poorly, in that they only used
the Hamilton Rating Scale for Depression, condition that
may inﬂuence the execution of a neuropsychological test on
memory. Finally, two studies [30,34] claim generically the use
of Petersen’s MCI criteria without any operational deﬁnition.
Information on the measurement tools used in the trials is
provided in Text S1.
The use of this range of diagnostic criteria was an
important source of clinical heterogeneity among the
populations enrolled, except for two trials [32,33] that used
essentially the same protocol.
Study Quality
The quality assessment was carried out for all of the
published trials [34,36,37] and for three of the unpublished
ones [31–33]. However, it should be kept in mind that scarce
or inadequate reporting does not necessarily imply that the
methodology was of low quality.
The Jadad scores ranged from 2 to 3, indicating medium to
low reporting quality (Table 2). The description of the
randomization process was adequate in only one trial [37].
In three trials, the description of this process was sufﬁcient
for understanding that the allocation of patients could not be
predicted [32,33,37]. In all trials, the blinded status of the
assessors, care providers, and participants was undermined by
the fact that ChEIs have clear side effects. Three studies
speciﬁed that the placebo was ‘‘indistinguishable’’ from the
drug [32,33,37]. In one trial, an independent panel veriﬁed in
double-blind conditions the occurrence of the primary
outcome, yet not of all the surrogate measures [37]. The
baseline characteristics of the participants were available only
for the published studies. Four trials used the intention-to-
treat (ITT) analysis [32,33,36,37]; however, only one carried
out a sensitivity analysis [37].
Efficacy and Adverse Events
As mentioned above, we were able to obtain the results for
six of the eight studies (Table 2). Conversion from MCI to AD
or dementia was considered as the primary end point in four
studies. In two studies, AD and dementia were diagnosed
according to, respectively, NINCDS-ADRDA (National In-
stitute of Neurological Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association) and DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition) criteria [31,37], whereas in the other two, only a
change in CDR score from 0.5 to 1.0 or higher was considered
[32,33]. No signiﬁcant differences emerged in the probability
of conversion between the treated groups and the placebo
groups. The rate of conversion ranged from 13% (over 2 y) to
25% (over 3 y) among treated patients, and from 18% (over 2
y) to 28% (over 3 y) among those in the placebo groups (Table
2). Only for two studies was it possible to derive point
estimates of the relative risk of conversion: 0.85 (95%
conﬁdence interval 0.64–1.12) [31], and 0.84 (0.57–1.25) [37].
A reduced likelihood of conversion to AD, compared to the
placebo group, was reported by one trial during the ﬁrst 12
mo of treatment, yet this result was not observed at the end of
the 3-y follow-up [37]. As discussed in the Cochrane review on
Table 2. Conversion Rates from Mild Cognitive Impairment to Alzheimer Disease or Dementia and Jadad Quality Score
Category Gal-INT-18 [33]:
Galantamine
Gal-INT-11 [32]:
Galantamine
InDDEX [31]:
Rivastigmine
Salloway [36]:
Donepezil
Petersen [37]:
Donepezil
Koontz [34]:
Galantamine
Duration of the study 2 y 2 y 3–4 y 24 wk 3 y 16 wk
Subjects completing the study (ChEI; placebo) — — 51%; 63% 68%; 83% 64%; 74% 50%; 36%
Conversion rate (ChEI; placebo) 17%; 21% 13%; 18% 17%; 21% — 25%; 28% —
Jadad quality score (0–5) 2 2 3 3 3 3
—, not reported.
doi:10.1371/journal.pmed.0040338.t002
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Mild Cognitive Impairment: A Reviewdonepezil, if we accept ‘‘an effect of donepezil in delaying AD
for 12 months we must also accept that it then accelerates the
appearance of AD after 18 months’’ [21].
The percentage of the study population that completed the
study ranged from 51% to 68% among those allocated to
treatment and from 36% to 83% among placebo recipients.
The percentage of persons who completed the study was
consistently lower for the treatment group, compared to the
placebo group, except in the Koontz trial (Table 2).
Furthermore, Petersen and colleagues reported that persons
with more severe cognitive impairment were more likely to
withdraw from the study and that there was a tendency for
treated individuals to withdraw from the trial earlier [37];
thus the missing data were not randomly distributed. No
study provided information that would allow the reader to
assess the potential bias due to differential dropout (e.g.,
concomitant disorders).
The response to treatment was also assessed using a range
of measures derived mainly from AD trials [19]. A total of 36
different scales, tests, and neuropsychological batteries, and
two measures of volumetric imaging, were used as either a
primary or a secondary end point (Table 3) (detailed
information on the measurement tools used in the trials is
provided in Text S1).
Efﬁcacy was measured on an ITT population in four trials
[32,33,36,37], and the last observation carried forward (LOCF)
method was used for missing data points in three of them
[32,33,36]. Only one trial adjusted the resulting p-values for
multiple comparisons [37].
In Figure 2 are reported the point estimates and
conﬁdence intervals for the outcomes for which speciﬁc
results from the original studies were available. Data from
one trial [34] were not considered as they actually refer to ten
of the 19 trial participants, and they were not based on ITT
analysis. Statistically signiﬁcant differences emerged only for
the mean rate of brain volume atrophy, and the CDR–Sum of
Table 3. Primary (I) and Secondary (II) Efficacy Measures Used in the Trials Included
Category Measure Study
Gal-INT18
[33]
Gal-INT11
[32]
InDDEX
[31]
Salloway
[36]
Petersen
[37]
Koontz
[34]
Cognitive ADAS-cog — — II — II —
ADAS-cog 11 II II — — — —
ADAS-cog 13 II II — II — —
ADAS-cog MCI I I — — — —
BNT — — II II II —
Buschke Reminding — — II — — —
CANTAB — — — — — I
Category Fluency test — — — — II —
Clock Drawing test — — II — II —
CVLT — — — — — II
Delayed word list recall — — II — — —
Digit-Backward test — — — — II —
Digit Cancellation Task — — II — — —
DSST II II — — — —
Letter Numbering sequence — — II — — —
Maze test — — II II II —
Number cancellation test — — — II II —
NYU Paragraph Recall, Revised
(immediate/delayed)
II II II I II —
Symbol Digit Modalities task — — II II II —
Verbal Fluency Category — — II II — —
Warrington Faces Test — — II — — —
WMS-R — — — II — —
Global and Clinical ADCS-CGIC — — — I — —
CDR II II II — II —
CDR-SB I, II I, II — — II —
CGIC-MCI — — — I — —
GDS — — II — II —
MMSE — — II — II —
PGA — — II — —
QOL-AD — — II — —
Activities of daily living ADCS-ADL — — II — — —
ADCS-ADL-MCI II II — — II —
FAQ — — — — — II
Neuropsychiatric symptoms Beck Depression Inventory — — II — — —
NPI — — II — — —
Benton Judgement — — II — — —
Neuroimaging MRI hippocampal volume — II — — — —
MRI whole brain volume — II II — — —
Efficacy measures are described in Text S1.
doi:10.1371/journal.pmed.0040338.t003
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Mild Cognitive Impairment: A Reviewthe Boxes scores for galantamine [32]; and the cognitive
functions evaluated by ADAS-cog 13 for donepezil [36].
When adjusting for multiple comparisons using the
Bonferroni method, only the difference in the rate of atrophy
in the whole brain remained signiﬁcant.
The percentages of participants with at least one adverse
event (AE), those with severe AEs, and those who discon-
tinued for AEs were reported in only four trials [31–33,36].
Three trials described AEs occurring in at least 5% of
participants [31,36,37]. One trial did not report AEs at all [34].
The percentage of participants with at least one AE was
very high among both treatment recipients (88%–96%) and
placebo recipients (73%–93%) (Table 4). The rate of
discontinuation due to AEs was consistently higher for
treatment recipients (21%–24%) than for placebo recipients
(7%–13%). The data on causes of death were overall
inadequate. Only GAL-INT-11 (the protocol for the galant-
amine RCT [32]) reported all of the causes of death for each
study arm: one death occurred among placebo recipients
(arrhythmia and cardiac arrest) and six deaths occurred
among treatment recipients [32].
Discussion
The use of ChEIs in persons with MCI, for periods ranging
from less than 4 mo to 3 y, was not associated with any delay
in the onset of AD or dementia. Furthermore, according to
the 38 surrogate measures used in the trials, and after
appropriate adjustment for multiple comparisons, only
neuroimaging showed a signiﬁcant difference in favour of
the drug being studied; the clinical implications of this
ﬁnding are unclear [32]. Moreover, the safety proﬁle showed
that the risks associated with ChEIs are not negligible.
These results conﬁrm for the all class of ChEIs those
reported by two Cochrane systematic reviews. The ﬁrst review
was on the effect of galantamine in patient with MCI or AD;
the authors concluded that the clinical beneﬁt was marginal
Figure 2. Effect of Treatment on the Efficacy Measures Used in the Included Studies
Data points represent change in the treated groups versus the placebo groups. For each measure the range of possible scores are reported, when
available, in square brackets.
*Z-cognitive is a composite score based on a ten-test neuropsychological test battery in the InDDex study, and on a eight-test battery in the Petersen
study.
Doi:10.1371/journal.pmed.0040338.g002
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Mild Cognitive Impairment: A Reviewbut ‘‘galantamine use in MCI is not recommended due to its
association with an excess death rate’’ [20]. The second review
[21] included two trials on donepezil, one that showed some
promise for certain outcomes [36], and the other that showed
side effects and no evidence of efﬁcacy [37]. The authors’
conclusion was ‘‘there is no evidence to support the use of
donepezil for patient with MCI. The putative beneﬁts are
minor, short lived and associated with signiﬁcant side effects’’
[21].
A recent meta-analysis on four trials using progression to
dementia as the major parameter of efﬁcacy found an
approximate 24% reduction of risk of conversion to
dementia and an increase of more than 50% in adverse
events [38]. This pooled effect estimate was obtained
notwithstanding the substantial heterogeneity of populations
enrolled nor the methods of assessment. Moreover, the
relative risk of conversion could not be calculated for the
two trials on galantamine, as original data were necessary to
apply a Cox proportional hazard ratio model.
Our revision of all the trials on the three drugs permits an
overall comparison across the studies with respect to design,
objective, and deﬁnition of MCI.
The primary end point of prevention trials should be the
time to development of dementia or AD; this measure was
used in only four of the trials included in this review [31–
33,37]. The efﬁcacy of the study drugs was also assessed on
cognitive and/or functional domains applying a number of
surrogate measures: 38 different instruments were used,
considering simultaneously a wide range of hypotheses.
Moreover, most of these measures have been developed for
AD trials and transposed to MCI trials without ﬁrst having
been validated. However, it has already been claimed that the
validation process is not simple, given that it is subordinate to
the deﬁnition of MCI as a clinical entity, which itself is
controversial [10–14,24].
A ﬁrst important consequence of this uncertainty is that
the trial populations were not homogeneous, even if the same
criteria proposed by Petersen and colleagues were used [9].
Petersen and colleagues, in fact, did not specify which
neuropsychological tests or instrument should be used to
operazionalise MCI criteria. The predictable consequence of
this ﬂexibility is that operationalisation of the MCI diagnostic
criteria differed widely among the trials, giving rise to quite
different populations.
This was conﬁrmed in a recent study in which the authors
applied the enrolment criteria used in the GAL-INT-11,
InDDEX, and Petersen et al. trial to the same cohort of 150
participants sampled in a memory clinic [15]. The study
found that MCI was diagnosed in 51.3%, 21.3%, and 16.7% of
the participants when applying, respectively, the criteria of
GAL-INT-11, InDDEX, and Petersen’s trial. This wide clinical
heterogeneity among the study populations is the main
reason for not combining the included studies in a pooled
analysis.
In general, the uncertainty regarding MCI as a clinical
entity raises the question as to the scientiﬁc validity and
ethical value of these trials [39]. In fact, the requirement of
scientiﬁc validity regards not only the mere technical domain
of the correct design and conduct of a clinical trial. It is also a
criterion to apply to the soundness of the clinical question
approached by the experimentation. In a recent New England
Journal of Medicine editorial, Karlawish used the concept of the
‘‘logic of clinical purpose’’ in discussing the role of clinical
trials in AD [40]. According to this idea, ’’Clinical trials are
logically grounded in and ethically justiﬁed by the way they
reﬂect and contribute to clinical practice.’’ As some
participants in a 2006 workshop dedicated to MCI have
reported, no agreement emerged during the conference as to
the clinical utility of MCI, in that there was no consensus on
the nature of MCI (is it a syndrome, a risk state, a new
diagnosis?) [13].
Moreover, there is epidemiological evidence that the
diagnosis of MCI is often unstable, and many persons labelled
as having MCI may revert over time to normal cognition [16–
Table 4. Summary of Data on Adverse Events Extracted from the Included Trials
Published or
Unpublished
Study Study Drug Any AEs,
% Participants,
ChEI;
Placebo
Severe AEs,
% Participants,
ChEI;
Placebo
Discontinuation
for AEs,
% Participants,
ChEI;
Placebo
Deaths, n,
ChEI;
Placebo
Causes of Death
Unpublished
a InDDEX 1999 [31] Rivastigmine 96%; 93% 28%; 30% 24%; 13% 7; 13 —
GAL-INT-18 2001 [33] Galantamine 90%; 86% 19%; 21% 23%; 10% 7; 0 Two sudden deaths,
five not reported
GAL-INT-11 2001 [32] Galantamine 90%; 88% 18%; 17% 21%; 9% 6; 1 Galantamine: two suicides, two
myocardial infarctions, one
bronchial cancer and sudden
death, one cerebrovascular
disorder and syncope;
placebo: one arrhythmia
Published Salloway 2004 [36] Donepezil 88%; 73% 4%; 4% 22%; 7%
b 0; 1 —
Petersen 2005 [37] Donepezil — — — 7; 5 —
Koontz 2005 [34] Galantamine — — — — —
—, not reported.
aThe year refers to the study start.
b Excluding deaths.
doi:10.1371/journal.pmed.0040338.t004
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Mild Cognitive Impairment: A Review18,23,24]. Since none of the trials provided information on
this phenomenon, it cannot be excluded that some partic-
ipants may have received the treatment despite having
reverted to normal cognition.
A possible limitation of our review was that there was no
information on the results of two trials: one of the trials was
suspended for unknown reasons [35], and the other was
completed in September 2004, yet the results are not yet
available [30]. Nonetheless, this probably did not bias the
risk–beneﬁt proﬁle of ChEIs for MCI patients, given that
publication bias usually works in favour of the study drugs.
With regard to the quality of reporting of the trials, a
common shortcoming was the inadequate description of the
randomization and blinding procedures. Other important
weaknesses were the very poor description of dropouts and of
harm-related issues (e.g., only one trial reported all of the
causes of death for each study arm). Our review was not
blinded to the trials. This may have inﬂuenced our assess-
ments of the quality of primary studies, although, given the
simplicity of the Jadad scale, distorted judgements are very
unlikely.
On average, the maximum dosage of ChEIs was used in all
trials, which probably contributed to the high frequency of
dropout and discontinuation for AEs. Mortality was higher
among persons receiving donepezil or galantamine, com-
pared to placebo recipients, and this excess in mortality
seems to have been prevalently due to cardio- and cerebro-
vascular diseases. In GAL-INT-11 [32] and GAL-INT-18 [33],
the regulatory authorities considered the increased mortality
as noteworthy and stressed that ChEIs are not indicated for
MCI patients; they also recommended that ChEIs be used with
caution in AD patients with cardiovascular risk factors
[22,41,42].
Recently, some authors have suggested the rating of medial
temporal atrophy, performed using magnetic resonance
imaging, as a routine clinical evaluation to identify ‘‘individ-
uals with MCI who are destined to progress to dementia
within 3 years’’ [43].
MCI seems to be an example of a risk factor conceptualised
as a clinical condition, and it is surely still too heterogeneous
and unpredictable as a clinical entity to enable researchers to
establish its exact role in the progression toward dementia.
From a public health point of view, it seems reasonable to
afﬁrm that additional research for clearly deﬁning MCI is
needed before testing new pharmacological treatments.
When there is controversy surrounding the deﬁnition of a
condition or disease, even inconclusive results from RCTs can
be used to suggest treatment for persons tagged with some
‘‘pre-disease’’ condition. For example, in Italy an extimated
27% of patients diagnosed with MCI are prescribed chol-
inesterase inhibitors off-label [44]; it is likely that this
situation is not limited to Italy.
The philosophy of widening the boundaries of treatable
illness corresponds to the strategy of expanding the market
for new products. This has been recently described as
‘‘disease mongering’’ [45,46]. This issue was also recently
addressed by Britain’s House of Commons Health Commit-
tee: ‘‘[...] There has been a trend towards categorising more
and more individuals as ‘abnormal’ or in need of drug
treatment [...]. Where disease awareness campaigns end and
disease mongering begins is a very indistinct line’’ [47].
This review shows that the diagnosis of MCI is uncertain
and variable, and whatever criteria are adopted, ChEIs are
not effective in either preventing AD or improving cognitive
functions in persons with MCI. These drugs may even be
harmful in some people. Thus the alleged clinical implica-
tions of the trials, as claimed by some of the authors, are not
justiﬁed by the data.
Supporting Information
Text S1. Measurement Tools Used in the Trials
Found at doi:10.1371/journal.pmed.0040338.sd001 (57 KB DOC)
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Mild Cognitive Impairment: A ReviewEditors’ Summary
Background. Worldwide, more than 24 million people have dementia, a
group of brain disorders characterized by an irreversible decline in
memory, problem solving, communication, and other ‘‘cognitive’’
functions. The commonest form of dementia is Alzheimer disease (AD).
The risk of developing AD increases with age—AD is rare in people
younger than 65 but about half of people over 85 years old have it. The
earliest symptom of AD is usually difficulty in remembering new
information. As the disease progresses, patients may become confused
and have problems expressing themselves. Their behavior and person-
ality can also change. In advanced AD, patients need help with daily
activities like dressing and eating, and eventually lose their ability to
recognize relatives and to communicate. There is no cure for AD but a
class of drugs called ‘‘cholinesterase inhibitors’’ can sometimes
temporarily slow the worsening of symptoms. Three cholinesterase
inhibitors—donepezil, rivastigmine, and galantamine—are currently
approved for use in mild-to-moderate AD.
Why Was This Study Done? Some experts have questioned the efficacy
of cholinesterase inhibitors in AD, but other experts and patient support
groups have called for these drugs to be given to patients with a
condition called mild cognitive impairment (MCI) as well as to those with
mild AD. People with MCI have memory problems that are more severe
than those normally seen in people of their age but no other symptoms
of dementia. They are thought to have an increased risk of developing
AD, but it is not known whether everyone with MCI eventually develops
AD, and there is no standardized way to diagnose MCI. Despite these
uncertainties, several clinical trials have investigated whether cholines-
terase inhibitors prevent progression from MCI to AD. In this study, the
researchers have assessed whether the results of these trials provide any
evidence that cholinesterase inhibitors can prevent MCI progressing to
AD.
What Did the Researchers Do and Find? The researchers conducted a
systematic review of the medical literature to find trials that had
addressed this issue, which met criteria that they had defined clearly in
advance of their search. They identified three published and five
unpublished randomized controlled trials (studies in which patients
randomly receive the test drug or an inactive placebo) that investigated
the effect of cholinesterase inhibitors on the progression of MCI. The
researchers obtained the results of six of these trials—four examined the
effect of cholinesterase inhibitors on the conversion of MCI to clinically
diagnosed AD or dementia (the primary end point); all six examined the
effect of the drugs on several secondary end points (for example,
individual aspects of cognitive function). None of the drugs produced a
statistically significant difference (a difference that is unlikely to have
happened by chance) in the probability of progression from MCI to AD.
The only statistically significant secondary end point after adjustment for
multiple comparisons (when many outcomes are considered, false
positive results can occur unless specific mathematical techniques are
used to prevent this problem) was a decrease in the rate of brain
shrinkage associated with galantamine treatment. More patients treated
with cholinesterase inhibitors dropped out of trials because of adverse
effects than patients given placebo. Finally, in the one trial that reported
all causes of deaths, one participant who received placebo and six who
received galantamine died.
What Do These Findings Mean? These findings suggest that the use of
cholinesterase inhibitors is not associated with any delay in the onset of
clinically diagnosed AD or dementia in people with MCI. They also show
that the use of these drugs has no effect on most surrogate (substitute)
indicators of AD but that the risks associated with their use are not
negligible. However, because MCI has not yet been clearly defined as a
clinical condition that precedes dementia, some (even many) of the
patients enrolled into the trials that the researchers assessed may not
actually have had MCI. Thus, further clinical trials are needed to clarify
whether cholinesterase inhibitors can delay the progression of MCI to
dementia, but these additional trials should not be done until the
diagnosis of MCI has been standardized.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040338.
  An essay by Matthews and colleagues, in the October 2007 issue of
PLoS Medicine, discusses how mild cognitive impairment is currently
diagnosed
  The US Alzheimer’s Association provides information about all aspects
of Alzheimer disease, including fact sheets on treatments for
Alzheimer disease and on mild cognitive impairment
  The UK Alzheimer’s Society provides information for patients and
caregivers on all aspects of dementia, including drug treatments and
mild cognitive impairment
  The UK charity DIPEx provides short video clips of personal
experiences of care givers of people with dementia
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